DK1611252T3 - In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren - Google Patents

In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren

Info

Publication number
DK1611252T3
DK1611252T3 DK04723215T DK04723215T DK1611252T3 DK 1611252 T3 DK1611252 T3 DK 1611252T3 DK 04723215 T DK04723215 T DK 04723215T DK 04723215 T DK04723215 T DK 04723215T DK 1611252 T3 DK1611252 T3 DK 1611252T3
Authority
DK
Denmark
Prior art keywords
cell carcinoma
vitro method
transitional cell
bladder
cancer
Prior art date
Application number
DK04723215T
Other languages
English (en)
Inventor
Roman Jose Javier Gomez
Gonzalez Jorge Cuevas
Martinez Antonio Martinez
Buela Laureano Simon
Cruz Simon Santa
Jimenez Maria Saenz
Vila Miguel Molina
Sanchez-Vallejo Corina Junquera
Original Assignee
Progenika Biopharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenika Biopharma Sa filed Critical Progenika Biopharma Sa
Application granted granted Critical
Publication of DK1611252T3 publication Critical patent/DK1611252T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04723215T 2003-03-26 2004-03-25 In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren DK1611252T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200300708 2003-03-26
PCT/EP2004/003219 WO2004085676A1 (en) 2003-03-26 2004-03-25 In vitro method to detect bladder transitional cell carcinoma

Publications (1)

Publication Number Publication Date
DK1611252T3 true DK1611252T3 (da) 2009-11-23

Family

ID=33041266

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04723215T DK1611252T3 (da) 2003-03-26 2004-03-25 In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren

Country Status (7)

Country Link
US (1) US8124331B2 (da)
EP (1) EP1611252B1 (da)
AT (1) ATE437963T1 (da)
DE (1) DE602004022266D1 (da)
DK (1) DK1611252T3 (da)
ES (1) ES2330634T3 (da)
WO (1) WO2004085676A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US9089601B2 (en) * 2006-07-10 2015-07-28 University Of Rochester Pre- and intra-operative imaging of bladder cancer
RU2321856C1 (ru) * 2006-12-12 2008-04-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ диагностики поверхностных переходноклеточных карцином мочевого пузыря
ES2323927B1 (es) * 2007-03-30 2010-05-14 Laboratorios Salvat, S.A. Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga.
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
TWI507205B (zh) 2009-03-25 2015-11-11 Genentech Inc 抗fgfr3抗體及使用方法
CA2878183A1 (en) * 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
CA2886002C (en) * 2012-09-27 2020-06-09 Chugai Seiyaku Kabushiki Kaisha Fgfr3 fusion gene and pharmaceutical drug targeting same
EP4063516A1 (en) * 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
ES2921701T3 (es) 2016-08-05 2022-08-30 Univ New York State Res Found Queratina 17 como un biomarcador para el cáncer de vejiga
IL300623A (en) 2020-08-21 2023-04-01 Genzyme Corp Anti-FGFR3 antibodies and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
AU5214500A (en) * 1999-05-05 2000-11-21 Centre National De La Recherche Scientifique (C.N.R.S.) Means for detecting and treating pathologies linked to fgfr3
AU2002329540A1 (en) * 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof

Also Published As

Publication number Publication date
EP1611252B1 (en) 2009-07-29
ES2330634T3 (es) 2009-12-14
WO2004085676A1 (en) 2004-10-07
US8124331B2 (en) 2012-02-28
US20070092878A1 (en) 2007-04-26
DE602004022266D1 (de) 2009-09-10
EP1611252A1 (en) 2006-01-04
ATE437963T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
Gu et al. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
BRPI0810336A2 (pt) "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
BR112023020219A2 (pt) Anticorpos anti-il-2r agonistas e métodos de uso
ATE547420T1 (de) Azepinoindol und pyridoindolderivate als pharmazeutische mittel
MX2009003122A (es) Inhibidores de tirosina cinasa de bruton.
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BR112012030625A2 (pt) uso de inibidores de tirosina quinase de bruton (btk)
MX2011006091A (es) Inhibidores de imidazopirazina syk.
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
EP2279244A4 (en) METHOD AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
NO20052923L (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
UA88440C2 (ru) ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
DK1611252T3 (da) In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren
WO2020176654A8 (en) Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
MA20150436A1 (fr) Préparation pharmaceutique
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
Bui et al. Effects of CYP3A modulators on the pharmacokinetics of naloxegol
NO20091628L (no) Kombinasjonsmedikament
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
WO2008021048A3 (en) Adp-ribosyltransferase based methods and compositions